Vivozon Pharmaceutical비보존 제약
082800 · KOSDAQ · ₩082800 · 비보존 제약
₩3,095▲ ₩160 (5.45%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 36.0% | 40.8% | 51.8% | 43.9% | 34.5% | 34.1% |
| Operating margin | −37.5% | −32.3% | 3.3% | 3.6% | −31.4% | −31.1% |
| Net margin | −65.2% | −54.6% | −11.4% | −4.7% | −65.1% | −120.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −15.2% | −32.3% | +22.8% | +20.7% | +2.3% | — |
| Operating income growth | +1.4% | −771.7% | +10.4% | +113.9% | −3.4% | — |
| Net income growth | −1.2% | −224.8% | −197.3% | +91.3% | +44.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −39.1% | −36.2% | −9.5% | −3.2% | −40.3% | −81.6% |
| Return on assets | −18.9% | −18.5% | −5.6% | −1.9% | −20.6% | −36.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 71.6% | 127.7% | 73.3% | 66.9% | 76.8% | 124.7% |
| Net debt to equity | 22.6% | 49.2% | 24.2% | 21.4% | 39.6% | 38.9% |
| Current ratio | 66.1% | 43.2% | 61.5% | 69.7% | 61.1% | 108.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Vivozon Pharmaceutical / 비보존 제약 / 082800 / KRX:082800
Source: KRX statistical information